We examined whether the enrichment score of CD28+PD-1+ Tc cells could accurately predict chemotherapy sensitivity in patients with HCC, investigating the clinical efficacy of vinorelbine (Figure 5D), staurosporine (Figure 5E), sepantronium bromide (Figure 5F), docetaxel (Figure 5G), daporinad (Figure 5H), and bortezomib (Figure 5I) in HCC treatment (Supplementary Table S12). This evidence concerns the gene CD28 and hepatocellular carcinoma.